Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies (TARGET-TP)

Phase 3

Active, not recruiting

• Conditions: Thromboembolism; Lung Cancer; Bowel Cancer; Pancreatic Cancer; Liver Cancer; Oesophageal Cancer; Stomach Cancer; Cancer - Lung - Non small cell; Cancer - Lung - Small cell; Cancer - Bowel - Anal

• Registration Number: ACTRN12618000811202
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-11
• Last Update Posted: 24 October 2022

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 328

Inclusion Criteria

1.Patient is 18 years of age or older
2.Patient has a confirmed histological diagnosis of any gastrointestinal or lung cancer
3.Patient is newly diagnosed treatment-naïve or is previously treated with newly relapsed or progressive disease
4.Patient is being considered for, but has not commenced anticancer therapy including chemotherapy and/or radiotherapy and/or immunotherapy and/or targeted therapies, within neoadjuvant, adjuvant, curative, or palliative treatment settings
5.Patient has expected life expectancy of at least six months, as estimated by their treating clinician
6.Patient has provided written confirmation of informed consent on participant information and consent form

Exclusion Criteria

1.Patients who have already commenced anticancer therapy
2.Patients with a clinical indication for therapeutic anticoagulation (antiplatelet agents such as clopidogrel and aspirin are permitted)
3.Patients with a contraindication to anticoagulation and/or specifically low molecular weight heparin
4.Cancer diagnosis other than those specified in inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Objectively confirmed symptomatic or asymptomatic thromboembolism.<br><br>All thromboembolic events must be confirmed by appropriate standard diagnostic investigations such as radiological imaging for DVT or PE and cardiac investigations for suspected myocardial infarct. Study specific imaging will not be performed. A blinded clinical review panel will directly assess and review all radiological and cardiac investigations to confirm events. [ At time of any routine imagining for cancer response or at clinical suspicion of thromboembolism, until six months after randomisation.<br><br>]